Follows Chinese patients with NMOSD treated with satralizumab in routine care
Observes outcomes in Chinese people with NMOSD receiving satralizumab in routine practice.
Plain-language title generated from the registry record
Registry title: HANDLE-a Real World Study on Satralizumab in NMOSD
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 or older with NMOSD who test positive for AQP4 antibody, have had recent relapses, and are treated or about to be treated with satralizumab.
- Age
- 12 years or older
- Sex
- All sexes can join
- Disease stage
- NMOSD with EDSS score of 8.5 or lower at baseline. At least 1 relapse in the last 12 months or at least 2 relapses in the last 24 months.
- Earlier treatment
- Has received satralizumab, or is expected to receive it, for at least 12 months.
- Biomarker or test result
- Positive (seropositive) for AQP4 antibody.
Read by machine on 12 November 2026.
Where in China
- Huashan HospitalShanghai, ChinaContact: Ying MaoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Huashan Hospital
- Trial code
- NCT06829524
- Record updated
- 18 September 2026
- Original description
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.Read full original descriptionShow less
A Real-World Practical Model of Integrated Management for Chinese Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) on Satralizumab
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.
Inclusion: Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody, ≥ 12 years old; EDSS score ≤ 8.5 at baseline; Patients have experienced ≥ 1 relapse of NMOSD in the last 12 months or ≥ 2 relapses in the last 24 months; Patients should have received or be anticipated to receive satralizumab treatment for at least 12 months; Patients understand the study procedures and sign the informed consent form indicating willingness to participate in the study (for those < 18 years of age, the guardian should sign the informed consent form on behalf of the patient).
Exclusion: -.